Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | FABP1 | P07148 | 1/20 | 0.42 |
| ▸ | FABP6 | P51161 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | GRK2 | P25098 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075900 | 0.86 | HSD17B10 (0.49) | HSD17B10HPGDFABP1FABP6 | |
| SCHEMBL14075905 | 0.84 | HSD17B10 (0.51) | HSD17B10HPGDFABP1FABP6 | |
| SCHEMBL10054967 | 0.82 | ALDH1A1 (0.52) | HPGDFABP1FABP6ALDH1A1BACE1 | |
| SCHEMBL1413125 | 0.76 | FABP1 (0.67) | HPGDFABP1FABP6ALDH1A1BACE1 | |
| SCHEMBL28475529 | 0.74 | FABP1 (0.64) | HPGDFABP1FABP6ALDH1A1BACE1 | |
| SCHEMBL14075899 | 0.74 | BCHE (0.54) | ALDH1A1MAPTPKM | |
| SCHEMBL156743 | 0.72 | TP53 (0.54) | HSD17B10HPGDALDH1A1LMNACYP1A2 | |
| SCHEMBL22288520 | 0.72 | MAOB (0.50) | HSD17B10HPGDALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL16510057 | 0.71 | HPGD (0.41) | HPGDFABP1FABP6ALDH1A1BACE1 | |
| SCHEMBL332623 | 0.70 | MAOA (0.63) | HSD17B10HPGDALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | LIOTTA DENNIS C | 2008-09-18 | — | — | US | disclosed |
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | LIOTTA DENNIS C | 2008-09-18 | — | — | US | disclosed |
| WO-2008008852-A2 | CXCR4 ANTAGONISTS INCLUDING HETEROATOMS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | CXCL12, CXCR4, CXCR1 | HSD17B10 3791/4885HPGD 646/4885FABP1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.